OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Google Secures Pentagon AI Deal for Classified Projects 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
CAMBRIDGE, Mass., Feb. 08, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT) today announced the closing of its initial public offering of 6,785,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, including 885,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option. All of the shares in the offering were sold by Editas Medicine. The shares began trading on the NASDAQ Global Select Market on February 3, 2016.
Morgan Stanley and J.P. Morgan acted as joint book-running managers for the offering. Cowen and Company acted as lead manager, and JMP Securities acted as co-manager for the offering.
A registration statement relating to the securities being sold in this offering was filed with and declared effective by the Securities and Exchange Commission. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Jesse Baumgartner Stern Investor Relations, Inc. (212) 362-1200 [email protected]
